A share price of NewAmsterdam Pharma Company NV [NAMS] is currently trading at $19.50, down -1.22%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NAMS shares have gain 2.90% over the last week, with a monthly amount drifted -11.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on March 14, 2024, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $35. Previously, Guggenheim started tracking the stock with Buy rating on January 18, 2024, and set its price target to $30. On January 16, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $37 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $25 on October 30, 2023.
NewAmsterdam Pharma Company NV experienced fluctuations in its stock price throughout the past year between $5.63 and $26.35. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $19.50 at the most recent close of the market.
Analyzing the NAMS fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -12.99%, Pretax Profit Margin comes in at -12.56%, and Net Profit Margin reading is -12.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.46 and Total Capital is -0.62. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.75 points at the first support level, and at 17.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.26, and for the 2nd resistance point, it is at 21.01.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NewAmsterdam Pharma Company NV [NASDAQ:NAMS] is 10.15. As well, the Quick Ratio is 10.15, while the Cash Ratio is 6.82.
Transactions by insiders
Recent insider trading involved Topper James N, Director, that happened on Mar 26 ’24 when 8429.0 shares were purchased. Chief Scientific Officer, Kastelein Johannes Jacob Piete completed a deal on Mar 26 ’24 to sell 0.19 million shares. Meanwhile, Director LANGE LOUIS G bought 5000.0 shares on Feb 13 ’24.
